

- Immigration** *see* Diseases
- Imports** *see* Brand name drugs—Exclusivity period from imports; Drug patents
- IMS**, 16:74
- Income tax**
Research and development incentives, 9:25
- Income Tax Act** *see* Drugs and pharmaceuticals industry—Research and development
- India** *see* Drugs and pharmaceuticals industry—Marketing practices
- Inside Dope, The** *see* Pharmaceutical Manufacturers Association of Canada—Lobbying pressure, Erola
- Institut de recherches cliniques de Montréal, L'** *see* Witnesses
- Insulin** *see* Diabetes
- Insurance** *see* Drugs and pharmaceuticals—Costs/prices; Drugs and pharmaceuticals industry—Self-insurance
- Intellectual property**
Violations, 8:18; 10:11
See also Brand name drugs; Drug patents; Generic drugs
- Interleuken 2** *see* Biotechnology industry—Legislation; University of Western Ontario
- IUD** *see* Consumers
- James, Dr. Eric** (Cangene Corp.)
Patent Act (amdt.)(Bill C-22), 8:4, 34-6, 38-42, 44-9
- Japan** *see* Drug patents—Applications, Inspection by public; Drugs and pharmaceuticals industry—Stimulating
- Joint ventures** *see* Cangene Corp.
- Jones, Jean** (Canadian Association of Social Workers)
Patent Act (amdt.)(Bill C-22), 11:58, 65
- Karr, Gerry** (Canadian Medical Association)
Patent Act (amdt.)(Bill C-22), 13:3, 17-32
- Kay, Jack**
References, 3:51
See also Generic drugs—Market entry timeframe
- Kempling, Bill** (PC—Burlington)
American Association of Retired Persons, 15:64
Apotex, 3:37-8
Biotechnology industry, 8:46, 57; 12:51-2
Brand name drugs, 3:23-4, 61; 8:67; 10:33; 11:29; 14:52; 15:41-2
Canadian Diabetes Association, 14:53
Canadian Drug Manufacturers Association, 3:61
Canadian Infectious Disease Society, 15:14-5
Canadian Labour Congress, 6:58
Carr, references, 6:58
Chapman, references, 8:65-6
Coalition of Provincial Organizations of the Handicapped, 15:83
Consumers Association of Canada, 6:30-3
Dalhousie University Medical School, 11:17
Diabetes, 14:52
Disabled and handicapped, 15:84
Diseases, 15:15-6
Drug patents, 9:51; 16:58; 17:49-50
Drug plans, 11:29-31; 12:60
Drug Prices Review Board, 6:32, 59; 8:26; 10:30-1; 11:28; 12:51, 62; 14:52; 15:41, 52
- Kempling, Bill—Cont.**
Drugs and pharmaceuticals, 1:26-7; 6:43-4, 59-60; 8:26-7, 66-8; 9:52; 10:32; 11:30; 12:61; 14:29, 66; 15:28-9, 42, 84, 98
Drugs and pharmaceuticals industry, 1:27; 3:37; 6:59; 11:16; 15:41-2, 54
Generic drugs, 3:23-4; 8:66-7; 9:51-2; 10:30; 12:60, 74; 14:29-30, 54; 15:27-8, 63, 83-4, 96
Geriatrics, 15:53
Health care, 15:27, 29, 52
McMaster University Faculty of Health Sciences, 11:16-7
Medical Research Council, 15:15
Multinational corporations, 12:76
New Democratic Party, 3:38-9; 4:14
Nordic Laboratories, Inc., 11:16; 17:50
Patent Act (amdt.)(Bill C-22), 1:26-7, 43; 2:5, 8; 3:5, 22-5, 36-9, 61-2, 72; 4:6-8, 13-5, 17, 21-2, 24-7, 30-2; 6:30-3, 43-4, 58-60; 8:26-30, 33, 46-7, 57, 65-8; 9:51-2; 10:20, 30-3; 11:5, 16-8, 28-31; 12:50-2, 60-3, 74-6; 13:10; 14:29-30, 46, 51-4, 65-7, 78; 15:14-6, 27-9, 40-2, 52-4, 62-5, 70, 83-4, 95-8, 100; 16:21, 57-8, 64, 82, 87; 17:27-8, 37, 44, 46-7, 49-50
Patent Co-operation Treaty, 8:27-8
Pharmaceutical Manufacturers Association of Canada, 3:61
Physicians/researchers, 15:97
Procedure and Committee business
 Agenda and procedure subcommittee, Ms., 2:5; 3:5
 Bills, 1:9; 16:21; 17:43-4
 M. (White), amdt. (McCurdy), 4:32
 M. (Orlikow), 15:70
 Briefs, 3:22
 Meetings, 1:43
 M. (White), 4:8
 Members, 4:14
 Minister, 1:9-10
 Organization meeting, 1:7-10
 Printing, M., 1:7-8
 Quorum, M., 1:7
 Staff, M., 8:30
 Witnesses, 3:39; 8:29-30; 14:78
 M. (White), 4:6-7, 13-4, 21
 Amdt., 4:25-6
 Amdt. (McCurdy), 4:30-1
 M. (White), 8:33
 M. (Orlikow), 15:70
Public Service Alliance of Canada, 10:32
References
 White, Model-T remark, 14:30
 See also Drugs and pharmaceuticals—Costs/prices; Mackling, Hon. Alvin—References
Research and development, 15:40, 53
Scientific Research Tax Credit Program, 15:41
Senior citizens, 3:24; 15:62, 64
Terry Fox Medical Research Foundation, 15:83
Universities, 8:57; 11:16; 12:76; 14:65; 15:97
University of Western Ontario, 8:47
- Kennedy, Senator Edward**
References, 12:25
- Kerton, Robert** (Consumers Association of Canada)
Patent Act (amdt.)(Bill C-22), 6:3, 19-22, 24-31, 33
- Keystone Agriculture Producers**
Legislation, Bill C-22 opposing, 8:44; 16:16
- Kidney disease**, 14:43-4
Drug treatment, research, etc., 14:36